PRGO vs. CORT, JAZZ, SUPN, PCRX, NUVL, ALPN, ALKS, OGN, MDGL, and BBIO
Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Organon & Co. (OGN), Madrigal Pharmaceuticals (MDGL), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corcept Therapeutics presently has a consensus price target of $39.30, suggesting a potential upside of 64.57%. Perrigo has a consensus price target of $40.67, suggesting a potential upside of 23.61%. Given Perrigo's higher possible upside, research analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.
Corcept Therapeutics has a net margin of 21.86% compared to Corcept Therapeutics' net margin of -0.27%. Perrigo's return on equity of 21.98% beat Corcept Therapeutics' return on equity.
93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.7% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Corcept Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
In the previous week, Perrigo had 2 more articles in the media than Corcept Therapeutics. MarketBeat recorded 12 mentions for Perrigo and 10 mentions for Corcept Therapeutics. Perrigo's average media sentiment score of 0.54 beat Corcept Therapeutics' score of 0.53 indicating that Corcept Therapeutics is being referred to more favorably in the media.
Perrigo received 241 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.50% of users gave Corcept Therapeutics an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Summary
Corcept Therapeutics beats Perrigo on 12 of the 17 factors compared between the two stocks.
Get Perrigo News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
